Next Adjuvant 
Potenciates your vaccine

Features of our adjuvant

1. The strongest parenteral immune response after intramuscular vaccination

  • The antigen was intramuscular injected to mice two times in two weeks intervals in the presence of various adjuvant.
  • The immune response was monitored by the level of IgG in serum.
  • The adjuvant shows the superiority than others.

2. The strongest mucosal immune response after intranasal vaccination

  • The antigen was intranasally delivered to mice two times in two weeks intervals in the presence of various adjuvant.
  • The immune response was monitored by the level of IgG in serum and IgA in tear, nasal, and fecal.
  • The adjuvant shows the superiority than others.

3. Elicited a strong innate immune response in tumor model

4. Elicited a strong nasal immune response in mouse influenza model

5. Ready to uptake by immune cells 

  • The mouse blood cells can be stimulated and differentiated by the co-incubation of the adjuvant both in vivo and vitro.
  • No additional treatment is required for the delivery. 

6. High solubility

Up to 100 mg/ml solubility in DW or PBS

7. Defined mode of action

The action of mode is fully understood.

8.  A short half-life in vivo

Less than 20 minutes for half-life. Labile and easily removable after the required effect is exhausted.

9. An easy pharmacokinetics assay 

  • The assay for the pharmacokinetics of the adjuvant is well established.
  • More than 200 samples can be analyzed in a single day.

10. A long shelf-life

  • More than two years at ambient temperature in PBS
  • Can lypophlized without lost the efficacy 

11.  Can be mixed with any antigens in a single step without any special equipment 

Steps for the mixing with antigen

I. Take antigen in PBS 

II. Add the pre-determined amount of the adjuvant 

III. Invert mix for 2 minutes and aliquot


12. High recoverability of antigen

  • To determine the stability of the antigen in vaccine, the antigen should be recovered from the adjuvant mixture with a high efficacy. 
  • The antigen can be recovered from the adjuvant in 100% by a single step. 

13. Economical

The production cost of the adjuvant is the lowest considering the efficacy and versatility of the vaccine.

14. An established mass production system  

  • A month for the production of 100,000 dose
  • The current system can be further extended up to the 1 million dose per month.

15. Safety

  • ED50 of mouse by SC injection is about 2.5-5 ug.
  • LD50 of mouse by SC injection and Nasal droplet is about 100 ug.

16. Homogeneous manufacture and stringent QC

  • The adjuvant is a single peak in HPLC analysis.
  • The QC system for the consistent production has been estabilished.